Bevacizumab in ovarian cancer: State of the art and unanswered questions

Angela Musella, Laura Vertechy, Alessia Romito, Claudia Marchetti, Andrea Giannini, Valentina Sciuga, Carlotta Bracchi, Federica Tomao, Violante Di Donato, Francesca De Felice, Marco Monti, Ludovico Muzii, Pierluigi Benedetti Panici

Research output: Contribution to journalReview articlepeer-review


Ovarian cancer is a most lethal gynecologic tumor. The mainstay treatment is cytoreductive surgery followed by platinumbased chemotherapy. However, a high percentage of patients recur, thus needing multiple treatments with a frequently poor prognosis. In the last two decades, research has focused on the potential of target therapies to improve the survival of patients affected by ovarian cancer. Bevacizumab is one of the most studied target therapies, and it is approved for first- and second-line treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal tumors. Despite its widespread use with favorable results, controversy regarding patient selection and the best schedule, dosage, and timing of bevacizumab still exists. This review summarizes the state of the art on the use of bevacizumab for ovarian cancer in front-line, recurrence, and neoadjuvant settings. This study focuses on the results of pivotal trials, emerging data, ongoing research, and still unanswered questions about the most adequate dosage of bevacizumab and its potential activity after disease progression or rechallenge in previously treated patients.

Original languageEnglish
Pages (from-to)111-120
Number of pages10
Issue number2
Publication statusPublished - Oct 29 2016


  • Bevacizumab
  • Chemotherapy
  • Epitheia ovarian cancer
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Bevacizumab in ovarian cancer: State of the art and unanswered questions'. Together they form a unique fingerprint.

Cite this